AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.

Autor: Sayitoglu EC; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Luca BA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA., Boss AP; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Thomas BC; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Freeborn RA; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Uyeda MJ; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Chen PP; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Nakauchi Y; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Waichler C; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Lacayo N; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Bacchetta R; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.; Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Majeti R; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA.; Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA., Gentles AJ; Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA., Cepika AM; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA. acepika@stanford.edu., Roncarolo MG; Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA. mg1@stanford.edu.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA. mg1@stanford.edu.; Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA. mg1@stanford.edu.

Publikováno v: Leukemia [Leukemia] 2024 Jun; Vol. 38 (6), pp. 1246-1255. Date of Electronic Publication: 2024 May 09.

Epigenetic signature and key transcriptional regulators of human antigen-specific type 1 regulatory T cells.

Autor: Cepika AM, Amaya L, Waichler C, Narula M, Mantilla MM, Thomas BC, Chen PP, Freeborn RA, Pavel-Dinu M, Nideffer J, Porteus M, Bacchetta R, Müller F, Greenleaf WJ, Chang HY, Roncarolo MG

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Mar 12. Date of Electronic Publication: 2024 Mar 12.

Type 1 regulatory T cell-mediated tolerance in health and disease.

Autor: Freeborn RA; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, United States., Strubbe S; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, United States., Roncarolo MG; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, United States.; Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM), Stanford School of Medicine, Stanford, CA, United States.; Center for Definitive and Curative Medicine (CDCM), Stanford School of Medicine, Stanford, CA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Oct 28; Vol. 13, pp. 1032575. Date of Electronic Publication: 2022 Oct 28 (Print Publication: 2022).

BHLHE40 Regulates IL-10 and IFN- γ Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation.

Autor: Uyeda MJ; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Freeborn RA; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Cieniewicz B; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Romano R; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Chen PP; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Liu JM; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Thomas B; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Lee E; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Cepika AM; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States., Bacchetta R; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, United States., Roncarolo MG; Department of Pediatrics, Division of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, United States.; Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 Jul 07; Vol. 12, pp. 683680. Date of Electronic Publication: 2021 Jul 07 (Print Publication: 2021).

The role of Nrf2 in autoimmunity and infectious disease: Therapeutic possibilities.

Autor: Freeborn RA; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, United States., Rockwell CE; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, United States; Cell and Molecular Biology Program, Michigan State University, East Lansing, MI, United States. Electronic address: rockwelc@msu.edu.

Publikováno v: Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol] 2021; Vol. 91, pp. 61-110. Date of Electronic Publication: 2021 Apr 08.